Search
Displaying all 9 results
Selpercatinib
go.drugbank.com/drugs/DB15685
ApprovedInvestigational
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including cabozantinib, ponatinib, sorafenib, sunitinib, and...
Advanced RET-mutant medullary thyroid cancer
go.drugbank.com/conditions/DBCOND0129288Drugs: SelpercatinibMetastatic RET-mutant medullary thyroid cancer
go.drugbank.com/conditions/DBCOND0129286Drugs: SelpercatinibAdvanced RET-fusion thyroid cancer
go.drugbank.com/conditions/DBCOND0129292Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalPralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.
Metastatic RET-fusion thyroid cancer
go.drugbank.com/conditions/DBCOND0129294Locally Advanced Solid Neoplasm
go.drugbank.com/conditions/DBCOND0091517Metastatic RET-fusion Non Small Cell Lung Cancer
go.drugbank.com/conditions/DBCOND0129285Metastatic Solid Neoplasm
go.drugbank.com/conditions/DBCOND0080723